Mettler Toledo International Inc/ (MTD)
Health Care · Life Sciences Tools & Services · US stock · S&P 500 component
$1,622.29
▼ -16.75 (1.02%)
Fair valueOvervalued
$1,193 −26.5% to fair value
$596fair band $835–$1,551$1,789
Day's range
$1,613.05 – $1,646.63
52-week range
$1,023.05 – $1,659.70
About Mettler Toledo International Inc/
Mettler-Toledo makes precision instruments used to weigh, measure and analyse. Its range covers laboratory balances, pipettes and analytical instruments for research and quality control, industrial weighing and product inspection systems for factories and food producers, and retail weighing equipment. Customers include pharmaceutical and chemical companies, research laboratories, food producers and manufacturers. The group is organised mainly around geographic regions, with operations in Europe, Asia and North America.
The company earns money from instruments and from recurring service, consumables and software that customers need over the life of each device. Revenue was $4.1 billion over the last twelve months, with growth of 0.9% a year across the last three years. The operating margin is 28.2%, and the business earns a profit of 46% on the capital invested in it. Net debt is 1.8 times EBITDA, and no dividend is paid. On the site's X-Ray Score it receives 50 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $1,023.05 – $1,659.70Volume 263,900Daily, split-adjusted
Vitals
Market cap$32.7B
52-week range$1,023.05 – $1,659.70
Volume (last day)263,900
P/E (TTM)36.6
EBIT / EV yield3.4%
Free-cash-flow yield2.6%
Dividend yieldNo dividend
Revenue (TTM)$4.1B
Net income (TTM)$906M
Operating margin28.2%
Return on capital46.4%
Debt incl. leases$2.1B
Cash & securities$51M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$1,193model spread $1,123 – $1,281
Overvalued
−26.5% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $1,622
Undervalued < $835Fair $835 – $1,551Overvalued > $1,551
10-year DCF (market-scaled)
$1,278
Peer multiples
$1,216
Earnings power floor (not blended)
$444
Fundamentals-adjusted multiple
$1,084
Growth the price implies
18.3%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
32/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.4%
Free-cash-flow yield2.6%
Fair value vs price0.7×
Growth
Weak
33/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)0.9%
EPS growth (3y)3.1%
Growth consistency70%
Profitability
Strong
75/100
Earns high returns on the capital it uses.
See the numbers →
Return on invested capital46.4%
Operating margin28.2%
Gross profitability67.9%
Financial health
Fair
58/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score6 / 9
Net debt / EBITDA1.8×
Interest cover16.8×
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
-4.6%
Mar '25
+3.9%
Jun '25
+7.9%
Sep '25
+8.1%
Dec '25
+7.2%
Mar '26
+4.5%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.0B, diluted EPS $11.55.
Compare with peers
A Agilent Technologies,...42 IQV Iqvia Holdings Inc.42 TECH BIO-TECHNE Corp40 ILMN Illumina, Inc.39Other Life Sciences Tools & Services companies by X-Ray Score.
Fundamentals checklist
● 4 Good · ● 7 Average · ● 5 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldBad
Risk models
Altman Z''Good
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Average
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioBad
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 48/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $3.7B | $3.9B | $3.8B | $3.9B | $4.0B |
| Operating income | $993M | $1.1B | $1.1B | $1.1B | $1.1B |
| Net income | $769M | $873M | $789M | $863M | $869M |
| Operating cash flow | $909M | $859M | $966M | $968M | $956M |
| Operating margin | 26.7% | 28.7% | 27.7% | 28.7% | 27.8% |
| Free cash flow | $801M | $738M | $861M | $864M | $849M |
| Diluted EPS | $32.78 | $38.41 | $35.90 | $40.48 | $42.05 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 2 neutral · 2 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
| SMA 10 | 1,571.9 | Bullish |
| EMA 10 | 1,577.7 | Bullish |
| SMA 20 | 1,536.2 | Bullish |
| EMA 20 | 1,533.8 | Bullish |
| SMA 50 | 1,443.6 | Bullish |
| EMA 50 | 1,457.3 | Bullish |
| SMA 100 | 1,350.9 | Bullish |
| EMA 100 | 1,394.1 | Bullish |
| SMA 200 | 1,326.9 | Bullish |
| EMA 200 | 1,349.4 | Bullish |
Oscillators (daily)
| RSI (14) | 71.44 | Bearish |
| MACD (12, 26) | 54.08 | Bullish |
| Momentum (12) | 7.37 | Bullish |
| Stochastic %K (14) | 79.88 | Neutral |
| Williams %R (14) | -20.12 | Neutral |
| CCI (20) | 165.6 | Bearish |
Pivot points (classic, last session)
S3 1,574.4 | S2 1,593.7 | S1 1,608.0 | Pivot 1,627.3 | R1 1,641.6 | R2 1,660.9 | R3 1,675.2 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
MTD SEC filings
3 Aug 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
31 Jul 2026
10-QSEC EDGAR
Quarterly report
30 Jul 2026
8-KSEC EDGAR
Results of operations
13 May 2026
8-KSEC EDGAR
Director or officer change
11 May 2026
8-KSEC EDGAR
Shareholder vote results
8 May 2026
10-QSEC EDGAR
Quarterly report
7 May 2026
8-KSEC EDGAR
Results of operations
18 Mar 2026
DEF 14ASEC EDGAR
Proxy statement
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.